{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T17:18:31Z","timestamp":1776878311315,"version":"3.51.2"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The health and economic benefits of human papillomavirus (HPV) vaccination targeted at men who have sex with men (MSM) in developing settings have been rarely assessed. This study aimed to evaluate the effectiveness and cost-effectiveness of different HPV vaccination strategies among MSM in China.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A Markov model was developed to simulate HPV transmission dynamics among a total of 30.73 million MSM in China. The corresponding natural history included 6 states: susceptible, infected with low-risk subtypes, high-risk subtypes, anogenital warts and anal cancer, and deaths from anal cancer. MSM were divided into three age groups with cut-off points of 27 and 45 years. Alternative vaccination strategies were built by allocating bivalent, quadrivalent, nine-valent, or no vaccine to each of the groups. We generated the prevented infections and deaths by vaccination compared with baseline (no vaccination) and calculated incremental cost-effectiveness ratios (ICERs) to determine the optimal strategy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The model showed that in 10 years, at baseline, the existing cases of anogenital warts would reach 5,464,225 (IQR, 4,685,708-6,174,175); that of anal cancer would reach 1,922.95 (1,716.56-2,119.93), resulting in 940.55 (732.27-1,141.87) deaths. Under 50% vaccination coverage among one age group, the prevented cases of anogenital warts were maximized with quadrivalent vaccines allocated to MSM aged 27-45 years; that of anal cancer were maximized when offering nine-valent vaccines to the same group. Under 50% vaccination coverage among all groups, the lowest ICER (34,098.09 USD\/QALY, 31,146.54-37,062.88) was reached when only quadrivalent vaccines were provided. Based on this strategy, when the annual vaccination rate increased by 30%, the ICER (33,521.75 USD\/QALY, 31,040.73-36,013.92) would fall below three times China\u2019s per capita GDP. When the vaccine price decreased by 60%, the ICER was reduced to 7,344.44 USD\/QALY (4,392.89-10,309.23), indicating good cost-effectiveness taking China\u2019s per capita GDP as a threshold.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>HPV vaccination can effectively reduce the prevalence and mortality of related diseases among MSM in China, especially quadrivalent vaccines for anogenital warts and nine-valent vaccines for anal cancer. MSM aged 27-45 years were the optimal group for vaccination. Annual vaccination and appropriate adjustment of vaccine price are necessary to further improve the cost-effectiveness.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1197191","type":"journal-article","created":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T23:18:55Z","timestamp":1687562335000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Effectiveness and cost-effectiveness of human papillomavirus vaccination strategies among men who have sex with men in China: a modeling study"],"prefix":"10.3389","volume":"14","author":[{"given":"Yuwei","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Fan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinsheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leiwen","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luoyao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wujian","family":"Ke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huachun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.3390\/vaccines9121413","article-title":"Human papillomavirus vaccine efficacy and effectiveness against cancer","volume":"9","author":"Kamolratanakul","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.semcancer.2013.11.002","article-title":"The human papillomavirus family and its role in carcinogenesis","volume":"26","author":"Tommasino","year":"2014","journal-title":"Semin Cancer Biol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2016.12.017","article-title":"The low-risk papillomaviruses","volume":"231","author":"Egawa","year":"2017","journal-title":"Virus Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(13)60022-7","article-title":"Human papillomavirus and cervical cancer","volume":"382","author":"Crosbie","year":"2013","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.24406","article-title":"High prevalence of human papillomavirus type 58 in HIV infected men who have sex with men: a preliminary report in central Italy","volume":"88","author":"Sammarco","year":"2016","journal-title":"J Med Virol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6833a3","article-title":"Human papillomavirus-attributable cancers - united states, 2012-2016","volume":"68","author":"Senkomago","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1071\/sh10020","article-title":"Cancers attributable to human papillomavirus infection","volume":"7","author":"Grulich","year":"2010","journal-title":"Sex Health"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32986","article-title":"Cancer attributable to human papillomavirus infection in China: burden and trends","volume":"126","author":"Lu","year":"2020","journal-title":"Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/01.olq.0000187266.29927.11","article-title":"Men who have sex with men and human immunodeficiency virus\/sexually transmitted disease control in China","volume":"33","author":"Liu","year":"2006","journal-title":"Sex Transm Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.24943","article-title":"Prevalence of anal, oral, penile and urethral human papillomavirus in HIV infected and HIV uninfected men who have sex with men","volume":"90","author":"Ucciferri","year":"2018","journal-title":"J Med Virol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/s1473-3099(14)70994-6","article-title":"Site-specific human papillomavirus infection in adolescent men who have sex with men (HYPER): an observational cohort study","volume":"15","author":"Zou","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1004.e1001","DOI":"10.1016\/j.cmi.2016.08.011","article-title":"Anal human papillomavirus in HIV-uninfected men who have sex with men: incidence and clearance rates, duration of infection, and risk factors","volume":"22","author":"Don\u00e0","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187928","article-title":"Prevalence and risk factors of anal human papillomavirus infection among HIV-negative men who have sex with men in urumqi city of xinjiang uyghur autonomous region, China","volume":"12","author":"Tian","year":"2017","journal-title":"PloS One"},{"key":"B14","article-title":"Vaccination against HPV and view of new possibilities","volume":"83","author":"Mlad\u011bnka","year":"2018","journal-title":"Ceska Gynekol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"10762","DOI":"10.1038\/s41598-020-67668-1","article-title":"Human papillomavirus vaccine-associated premature ovarian insufficiency and related adverse events: data mining of vaccine adverse event reporting system","volume":"10","author":"Gong","year":"2020","journal-title":"Sci Rep"},{"key":"B16","first-page":"1964","article-title":"How to effectively control cervical cancer","volume":"19","author":"Hao","year":"2021","journal-title":"Dev Cancers"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.04.071","article-title":"Cost-effectiveness of nonavalent HPV vaccination among males aged 22 through 26 years in the united states","volume":"36","author":"Chesson","year":"2018","journal-title":"Vaccine"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.19914\/j.cjvi.2021037","article-title":"The current status of inclusion of vaccines from the 194 member states of the world health organization into the national immunization program","volume":"27","author":"Nan","year":"2021","journal-title":"China Vaccines Immunization"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2020.1858057","article-title":"The status of human papillomavirus vaccination recommendation, funding, and coverage in WHO Europe countries (2018-2019)","volume":"19","author":"Bonanni","year":"2020","journal-title":"Expert Rev Vaccines"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2001659","DOI":"10.2807\/1560-7917.Es.2021.26.50.2001659","article-title":"Human papillomavirus vaccination in the European Union\/European economic area and globally: a moral dilemma","volume":"26","author":"Colzani","year":"2021","journal-title":"Euro Surveill"},{"key":"B21","unstructured":"DiagnosisIV\n          Men are expected to be vaccinated with domestic nine-valent HPV vaccine2022"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(10)70219-x","article-title":"Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis","volume":"10","author":"Kim","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.07.078","article-title":"Targeted human papillomavirus vaccination for young men who have sex with men in Australia yields significant population benefits and is cost-effective","volume":"35","author":"Zhang","year":"2017","journal-title":"Vaccine"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2196\/14800","article-title":"Spatiotemporal analysis of men who have sex with men in mainland China: social app capture-recapture method","volume":"8","author":"Hu","year":"2020","journal-title":"JMIR Mhealth Uhealth"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-028933","article-title":"Relationship between gay app use and HIV testing among men who have sex with men in shenzhen, China: a serial cross-sectional study","volume":"9","author":"Wei","year":"2019","journal-title":"BMJ Open"},{"key":"B26","unstructured":"Statistical year book (2022)2022"},{"key":"B27","volume-title":"Intermediary analysis of persistent HPV infection and its influencing factors in men who have sex with men","author":"Tuo","year":"2019"},{"key":"B28","article-title":"Analysis of potential categories of human papillomavirus 16\/18 infection risk in men who have sex with men","volume":"22","author":"Gong","year":"2019","journal-title":"China Gen Med"},{"key":"B29","volume-title":"Epidemic characteristics and influencing factors of HIV, syphilis and herpes simplex virus type 2 among men who have sex with men in shenzhen","author":"Mao","year":"2021"},{"key":"B30","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3390\/pathogens11030314","article-title":"Incidence, persistence, and clearance of anal human papillomavirus among men who have sex with men in China: an observational cohort study","volume":"11","author":"Zhou","year":"2022","journal-title":"Pathogens"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1086\/656368","article-title":"Development of genital warts after incident detection of human papillomavirus infection in young men","volume":"202","author":"Arima","year":"2010","journal-title":"J Infect Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.10.052","article-title":"Clinical effectiveness and cost-effectiveness of quadrivalent human papillomavirus vaccination in HIV-negative men who have sex with men to prevent recurrent high-grade anal intraepithelial neoplasia","volume":"32","author":"Deshmukh","year":"2014","journal-title":"Vaccine"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.891991","article-title":"Natural history of anal papillomavirus infection in HIV-negative men who have sex with men based on a Markov model: a 5-year prospective cohort study","volume":"10","author":"Zhang","year":"2022","journal-title":"Front Public Health"},{"key":"B34","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/s1470-2045(12)70080-3","article-title":"Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis","volume":"13","author":"Machalek","year":"2012","journal-title":"Lancet Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28897","article-title":"Efficacy, immunogenicity and safety of the HPV-16\/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial","volume":"135","author":"Zhu","year":"2014","journal-title":"Int J Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/s2214-109x(20)30277-1","article-title":"Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis","volume":"8","author":"Zou","year":"2020","journal-title":"Lancet Glob Health"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males","volume":"364","author":"Giuliano","year":"2011","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.22088\/ijmcm.Bums.10.2.101","article-title":"Update on safety and efficacy of HPV vaccines: focus on gardasil","volume":"10","author":"Soliman","year":"2021","journal-title":"Int J Mol Cell Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N Engl J Med"},{"key":"B40","unstructured":"Price list of domestic HPV vaccine2021"},{"key":"B41","unstructured":"Hpv bivalent, quadrivalent and nine-valent vaccines price list2021"},{"key":"B42","unstructured":"WHO guide for standardization of economic evaluations of immunization programmes2019"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2017-053412","article-title":"Prevalence of human papillomavirus by geographical regions, sexual orientation and HIV status in China: a systematic review and meta-analysis","volume":"94","author":"Ma","year":"2018","journal-title":"Sex Transm Infect"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1063993","article-title":"Geosocial networking mobile applications use and HIV and other sexually transmitted infections among men who have sex with men in southern China: a cross-sectional study","volume":"11","author":"Guo","year":"2023","journal-title":"Front Public Health"},{"key":"B45","volume-title":"Anal carcinoma version 1. 2023-January 9, 2023","author":"Network","year":"2023"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab390","article-title":"Effectiveness of human papillomavirus (HPV) vaccination against penile HPV infection in men who have sex with men and transgender women","volume":"225","author":"Winer","year":"2022","journal-title":"J Infect Dis"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1177\/0956462418797864","article-title":"Prevalence and determinants of anal human papillomavirus infection in men who have sex with men and transgender women","volume":"30","author":"Cranston","year":"2019","journal-title":"Int J STD AIDS"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057204","article-title":"Acceptability of HPV vaccines and associations with perceptions related to HPV and HPV vaccines among men who have sex with men in Hong Kong","volume":"8","author":"Lau","year":"2013","journal-title":"PloS One"},{"key":"B49","doi-asserted-by":"publisher","first-page":"8763","DOI":"10.1038\/s41598-019-45258-0","article-title":"Human papillomavirus awareness and vaccine acceptability among men who have sex with men from mainland China","volume":"9","author":"Li","year":"2019","journal-title":"Sci Rep"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1496878","article-title":"Should human papillomavirus vaccination target women over age 26, heterosexual men and men who have sex with men? a targeted literature review of cost-effectiveness","volume":"14","author":"Soe","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.763564","article-title":"High human papillomavirus vaccine acceptability and cost-effectiveness of the Chinese 2-valent vaccine among men who have sex with men: a cross-sectional study in shenyang, China","volume":"8","author":"Ye","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B52","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/QAI.0b013e318247925e","article-title":"A comparison of sexual behavior patterns among men who have sex with men and heterosexual men and women","volume":"60","author":"Glick","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1097\/qai.0000000000003057","article-title":"Prevalence and risk factors of anal HPV infection in MSM living with HIV: identifying the target groups to prioritize for immunization","volume":"91","author":"Bruzzesi","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw845","article-title":"Impact and cost-effectiveness of selective human papillomavirus vaccination of men who have sex with men","volume":"64","author":"Lin","year":"2017","journal-title":"Clin Infect Dis"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-021-06309-y","article-title":"The cost-effectiveness of bivalent, quadrivalent, and nine-valent HPV vaccination in Asia: a systematic review","volume":"306","author":"Zhu","year":"2022","journal-title":"Arch Gynecol Obstet"},{"key":"B56","unstructured":"OrganizationWH\n          2022"},{"key":"B57","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1186\/s13063-021-05608-8","article-title":"Single-dose HPV vaccination efficacy among adolescent girls and young women in Kenya (the KEN SHE study): study protocol for a randomized controlled trial","volume":"22","author":"Barnabas","year":"2021","journal-title":"Trials"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-015-0308-4","article-title":"Dervaux, b. extending the human papillomavirus vaccination programme to include males in high-income countries: a systematic review of the cost-effectiveness studies","volume":"35","author":"Ben Hadj Yahia","year":"2015","journal-title":"Clin Drug Investig"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1197191\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T23:19:08Z","timestamp":1687562348000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1197191\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,22]]},"references-count":58,"alternative-id":["10.3389\/fimmu.2023.1197191"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1197191","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,22]]},"article-number":"1197191"}}